Table 3.
Summary of Worst Adverse Event Definitely, Probably, or Possibly Related to Treatment Per Patient Occurring Prior to Surgery
| Adverse Event | Grade | Capecitabine/Ir inotecan/RT (n=52) |
Capecitabine/O xaliplatin/RT (n=52) |
||
|---|---|---|---|---|---|
| Worst non-hematologic | 1 | 15 | (29%) | 11 | (21%) |
| 2 | 23 | (44%) | 27 | (52%) | |
| 3 | 11 | (21%) | 12 | (23%) | |
| 4 | 0 | (0%) | 2 | (4%) | |
| 5 | 0 | (0%) | 0 | (0%) | |
| Worst overall | 1 | 12 | (23%) | 9 | (17%) |
| 2 | 25 | (48%) | 29 | (56%) | |
| 3 | 14 | (27%) | 12 | (23%) | |
| 4 | 0 | (0%) | 2 | (4%) | |
| 5 | 0 | (0%) | 0 | (0%) | |
Adverse events were graded with CTCAE version 3.0.